Incyte Corporation
- Jurisdiction
United States - LEI
549300Z4WN6JVZ3T4680 - ISIN
US45337C1027 (INCY )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€21.73 236.4% overvalued - Financial strength (Piotroski F-Value)
-
6
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
7
/ 7
Profile
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. Read full profile
Fundamentals
- Net revenue
€3.91B - Gross margin
92.9% - EBIT
€1.01B - EBIT margin
25.8% - Net income
€742.81M - Net margin
19.0%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Denton Sheila A. | EVP & General Counsel |
|
|
|
|
| Denton Sheila A. | EVP & General Counsel |
|
|
|
|
| Denton Sheila A. | EVP & General Counsel |
|
|
|
|
| Stein Steven H | EVP & Chief Medical Officer |
|
|
|
|
| Denton Sheila A. | EVP & General Counsel |
|
|
|
|
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| Robert Bresnahan | May 31, 2025 | $1.00K–$15.00K |
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Sell |
| Ray Dalio |
|
|
|
Sell |
| Cathie Wood |
|
|
|
Buy |